Risk factors
Artiva Biotherapeutics (ARTV) risk factors
Item 1A of every Artiva Biotherapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors103 risks11 new2 dropped13 reworded
Artiva Biotherapeutics highlights a cash runway of $108.0 million into the second quarter of 2027, rising net losses, and new legislative and trade policy hurdles.
Filed Mar 10, 2026 - FY2024 10-K risk factors94 risks
Artiva Biotherapeutics is a clinical-stage biopharmaceutical company focused on unproven NK cell-based therapies with no approved commercial products.
Filed Mar 24, 2025